Articles tagged with Parkinsons Disease
The Aligning Science Across Parkinson’s initiative is launching a new funding opportunity to support collaborative research teams focused on understanding Parkinson’s disease heterogeneity across six focus areas. The grants will provide up to $3 million per year over three years.
Researchers from Lancaster University found a significant link between hearing impairment and an increased risk of developing Parkinson's disease. The study analyzed data from the UK Biobank, revealing a 57% higher risk for every 10-decibel increase in baseline hearing loss.
The project aims to improve the design of clinical trials for neurological conditions like stroke, Parkinson's disease, and vascular cognitive impairment and dementia. Community partners will facilitate academic and community partnerships for clinical trial development.
An international team has presented the first detailed picture of Huntington's disease protein clumps, known as fibrils. These elongated shapes differ in important ways from those in other diseases like Alzheimer's and Parkinson's, offering new insights into their role in the disease.
Researchers at the University of Arizona have made groundbreaking discoveries about levodopa-induced dyskinesia, a common complication in Parkinson's disease patients. The study found that the motor cortex becomes disconnected during dyskinetic episodes, leading to indirect causation rather than direct involvement.
A study found that propranolol reduces tremors in Parkinson's disease by inhibiting brain activity and reducing the amplifying effect of the stress hormone noradrenaline. Propranolol also works to reduce tremors at rest, suggesting a role for the stress system even when not under stress.
Researchers at Sanford Burnham Prebys used two sequencing methods to reveal new mRNAs associated with Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease. The study found vast mRNA isoform diversity in genes related to neurodegenerative diseases.
Researchers found that neuroinflammation in the hippocampus significantly alters motivation and behaviour in mice, particularly in females. This study suggests that treatments targeting hippocampal neuroinflammation could help reduce cognitive and behavioural symptoms in diseases such as Alzheimer's and Depression.
A new study published in the Journal of Medical Internet Research found that dancing improves both self-reported questionnaires and MRI brain scans in people with Parkinson disease. The study, conducted by York University researchers, showed a cumulative effect of dance classes on depression rates over 8 months.
Worsening heat waves exacerbate symptoms of neurodegenerative diseases like Parkinson's and dementia due to impaired sweating and blood flow. Doctors can take proactive steps by regularly screening for social isolation, providing resources, and utilizing telemedicine to monitor high-risk patients.
Researchers achieved near-perfect accuracy in detecting Parkinson's disease by analyzing brain responses to emotional situations. The study identified distinct patterns in how patients processed emotions, enabling accurate differentiation between patients and healthy controls.
A team of researchers at USC will receive funding to test a novel approach to slowing age-related cognitive decline, targeting the brain's lymphatic system. The grant aims to delay the onset of Alzheimer's and Parkinson's disease by clearing waste buildup.
Researchers will test the hypothesis that environmental manganese exposure is associated with the progression of Parkinson's symptoms and measure neuroinflammation in the brain using MRI scans. The study aims to inform environmental regulations for manganese worldwide and address an environmental justice concern.
Researchers at the University of Bonn are developing an AI foundation model to improve radiology and detect Parkinson's disease earlier. The 'Re-Start PD' project aims to identify the condition before symptoms appear, with potential applications in diagnosis, treatment, and prevention.
Ochsner Health has been chosen as a site for the Global Parkinson’s Genetics Program, a study aimed at identifying genetic links to Parkinson’s disease in underrepresented populations. The study will genotype over 150,000 individuals from around the world, providing population-specific insights into the basis of PD.
Researchers from the University of South Australia and Middle Technical University have developed an AI-powered voice analysis tool that can detect subtle changes in a person's voice to diagnose Parkinson's disease. The algorithm achieved high accuracy rates, up to 99%, and has the potential to improve early detection and remote monito...
Researchers at the University of Arizona Health Sciences have identified a potential new drug, PNA5, that targets cognitive symptoms in Parkinson's disease. The study found that PNA5 dials back inflammation in brain cells, which may prevent further degeneration and alleviate cognitive decline.
A new study reveals that patients with Parkinson's disease who exhibit rest tremor have more dopamine preserved in the caudate nucleus, a part of the brain important for movement planning and cognition. This challenges traditional understanding of how dopamine loss relates to PD symptoms.
The Speech Accessibility Project is working with two new partners, The Matthew Foundation and the Massachusetts Down Syndrome Congress, to recruit adults with Down syndrome and other conditions. The project aims to provide voice command devices to improve inclusion and employment opportunities for individuals with disabilities.
Mitophagy, a recycling process crucial for cellular health, increases and then declines in midlife brain cells, while lysosomes lose acidity with age. The study highlights the importance of developing new perspectives when studying brain aging in longer-lived species.
The C-Path initiative aims to generate drug development solutions that reflect each person's unique experience, leveraging diverse data and innovative technologies like AI and digital health. GEM-PD seeks to address unmet need in Parkinson's disease therapies by focusing on sex and gender differences.
Researchers have developed a simple model system to break down fibrils into their constituent single units or liquid droplets. This discovery has the potential to treat neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting pathological fibrils.
A study published in NPJ Parkinson’s Disease identified ecto-GPR37 as a potential biomarker of Parkinson’s disease progression. Patients with slow progression showed significant increases in ecto-GPR37 levels, suggesting its potential use for stratifying patients and guiding treatment.
Researchers at Tel Aviv University discovered a variant of TMEM16F protein that enhances the spread of Parkinson's pathology, potentially leading to new treatments. The study found that cells with the mutation secrete more pathological α-synuclein, which can form Lewy bodies and damage brain cells.
Critical Path Institute (C-Path) has announced key leadership appointments: Dr. Diane Stephenson promoted to Vice President of Neurology and Nadine Tatton welcomed as new Executive Director of CPAD Consortium. This move aims to advance neurodegenerative disease research, including Alzheimer's and Parkinson's diseases.
Healthy mice swing their tails actively to counterbalance tilts, producing significant angular momentum. This study provides a new experimental setup for assessing mouse balance and improves understanding of neurological mechanisms behind balance issues.
Researchers have developed a new protocol to exclusively access and quantify proteins carried by extracellular vesicles in the blood. This breakthrough may lead to early diagnosis of Parkinson's disease and other brain disorders, providing treatment opportunities before symptoms appear.
A new study led by the University of Michigan suggests that polyphosphate may play a crucial role in neurodegenerative diseases. Researchers discovered that polyphosphate is present in fibrils found in patients' brains, which could help explain their devastating effects.
Researchers at Kumamoto University identified G-quadruplexes as a central role in promoting alpha-synuclein aggregation, leading to neurodegenerative diseases. Inhibiting G4 assembly may prevent the onset of synucleopathies and position it as a promising target for early intervention.
Researchers found that participants with Parkinson's who performed rapid side-to-side eye movements showed reduced body sway and improved posture. In contrast, those with Parkinson's who made vertical saccadic eye movements experienced increased body instability.
Researchers develop transcranial ultrasound stimulation (TUS) as a non-invasive therapy for brain-related issues, with potential for personalized treatments. A 'search and rescue tool' for the brain, TUS enables precise targeting of specific areas before treatment.
Danielle Mor, a neuroscientist at the Medical College of Georgia, has been awarded $2.3 million to study the progression of Parkinson's disease through the use of C. elegans and innovative research approaches. Her goal is to understand how misfolded proteins spread from the gastrointestinal tract to the central nervous system.
Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
Researchers at Rutgers University found that people who took multiple courses of penicillin antibiotics had a modestly lower risk of developing Parkinson's disease. The study analyzed medical records from over 93,000 people in the UK and found an inverse dose-response relationship between antibiotic use and Parkinson's risk.
Researchers identified 254 genetic variants that shape key brain structures, including those controlling memory, motor skills, and addictive behaviors. The study provides a roadmap for understanding the genetic basis of brain-related disorders like Parkinson's disease and ADHD.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
A new study has identified two neuron types in the brainstem that induce REM sleep, revealing a potential cause of Parkinson's disease. The discovery provides insight into the neural circuitry underlying REM sleep and its relationship to neurodegenerative diseases.
Researchers from Charité have shown that deep brain stimulation using electrical impulses can accelerate movement and shorten delays in Parkinson's patients. By decoding the intent preceding voluntary movement seconds before action, they discovered that dopamine significantly speeds up this process.
A new magnetic gene therapy technology allows for precise control of specific brain circuits non-invasively with magnetic fields. The technology has shown promise in reducing abnormal movements in a mouse model of Parkinson's disease, and may have potential applications for treating psychiatric disorders and chronic pain.
Researchers create Lewy bodies in living dopaminergic neurons using human stem cells and find that immune challenge is crucial for their formation. The study identifies a previously unknown link between the immune system and neurological disease, suggesting that genetic predisposition may not be necessary for Parkinson's development.
Researchers at the University of California, Irvine have identified ophthalmic acid as an alternative neurotransmitter that reverses movement deficits in Parkinson's patients. The study found that ophthalmic acid binds to calcium-sensing receptors, offering a promising new avenue for treating movement disorders.
University of Rochester researchers have refined a noninvasive method called BL-OG that harnesses light to activate neurons in the brain. The technique has the potential to transform invasive procedures used to treat Parkinson's disease and other neurological conditions by providing a safer, less invasive alternative.
Researchers at NYU Langone Health will use visible-light OCT technology to detect biomarkers of neurodegenerative disease, including Alzheimer’s and Parkinson’s diseases. The study aims to identify retinal layers and monitor the effects of therapies.
Researchers trained an automatic speech recognizer on recordings from people with dysarthria related to Parkinson's disease, achieving a 30% accuracy improvement. The study, led by Mark Hasegawa-Johnson, provides valuable data for improving voice recognition devices.
Researchers at Fujita Health University have discovered critical impairments in purine metabolism and ATP recycling in patients with Parkinson's disease. The study highlights the importance of enhancing ATP production to slow disease progression and improve quality of life.
A team of scientists has identified a new genetic mutation in the SGIP1 gene that may cause early-onset Parkinsonism. The mutation affects brain cell communication, leading to synaptic dysfunction and recessive Parkinsonism. This discovery provides new insights into the disease's development and potential treatment strategies.
Researchers identified the external globus pallidus as responsible for impaired decision-making in mice with Parkinson's disease treated with pramipexole. Hyperactivation of this region was linked to poor risk-taking behavior and reduced effectiveness of treatments.
A novel drug molecule has been found to reactivate a crucial protein called parkin, which plays a key role in maintaining healthy brain cells. The study's findings lay the foundation for the design of personalized treatments for younger patients with specific mutations, offering new hope for a cure for Parkinson's disease.
A class of diabetes medications called SGLT2 inhibitors may reduce the risk of dementia and Parkinson's disease. The study found that people taking these drugs had a 20% lower risk of developing Alzheimer's disease, 30% lower risk of vascular dementia, and 20% lower risk of Parkinson's disease.
Researchers comprehensively reviewed cerebellar involvement in Parkinson's disease, highlighting the pathophysiological role of the cerebellum in motor and non-motor symptoms. Studies showed abnormal α-synuclein aggregation, neurodegeneration, and altered functional connectivity between the cerebellum and other brain regions.
A population-based study found that air pollution may lower Parkinson disease risk by modifying the disease phenotype and reducing dyskinesia. The study suggests a potential connection between air quality and Parkinson's disease progression.
Scientists have developed new therapies that selectively remove aggregated tau proteins associated with Alzheimer's disease in mice. The approach utilises TRIM21 to target tau aggregates, leaving healthy tau intact, and demonstrates potential for other brain disorders driven by protein aggregation.
Researchers at UCSF develop a method to target GTPases, enzymes involved in Parkinson's and many other diseases, by using drugs targeting the K-Ras oncogene. This approach reveals new drug binding sites that could not be predicted by computational tools.
A research team at Hiroshima University developed an analytical pipeline to identify unexploited genes associated with Parkinson's disease and oxidative stress. The study revealed two novel candidate genes, NUPR1 and UHRF2, which were absent from current gene-disease associations databases.
A study of 500,000 UK participants found insulin resistance associated with higher risk of 26 conditions, such as sleep disorders and pancreatitis, and lower risk of five diseases, including anaemia and Parkinson's disease. Insulin resistance also linked to increased mortality risk in women.
Researchers have developed an integrated optical sensor capable of detecting dopamine directly from unprocessed blood samples. This breakthrough enables low-cost and efficient screening tools for various neurological conditions and cancers.
A study published in The EMBO Journal reveals that PQBP3 plays a crucial role in stabilizing the nuclear membrane, which is destabilized in senescent cells and contributes to neurodegenerative disorders. PQBP3's dysfunction may lead to the degradation of Lamin B1, a protein essential for maintaining the nuclear membrane.
A new study published in Neurology found that acute kidney injury is associated with an increased risk of developing dementia. The study analyzed data from over 300,000 individuals and found a 49% higher risk of dementia overall, with significant increases for specific types of dementia such as Lewy body dementia and vascular dementia.
A new study published in Alzheimer's & Dementia found that cholinesterase inhibitors (ChEIs) may slow down cognitive decline in dementia with Lewy bodies over five years. ChEIs were also associated with a reduced risk of death in the first year after diagnosis.
A preclinical study found that enhancing PGK1 activity can restore neuronal energy supply in low-fuel conditions, preventing axon dysfunction and degeneration. The researchers also discovered the unexpected role of DJ-1 as an energy-supplying partner of PGK1.